You are visiting a website that is not intended for your region

The page or information you have requested is intended for an audience outside the United States. By continuing to browse you confirm that you are a non-US resident requesting access to this page or information.

Switch to the US site

COVID-19 Resource Center

Healthcare professionals can find help and guidance on how to benefit from our offerings to treat your patients, as well as other practical information and advice.

Read more


Year-End Report 2013

PRESS RELEASE                                                                                                                                                                                                                                                                                2014-01-28

Year-End Report 2013

Reporting period January – December

  • Order intake rose 4.0% to SEK 25,395 M (24,416) and grew organically by 4.0%
  • Net sales increased 4.3% to SEK 25,287 M (24,248), corresponding to organic growth of 4.2%
  • Profit before tax declined 8.2% to SEK 3,153 M (3,436)
  • Net profit decreased 9.3% to SEK 2,295 M (2,531)
  • Earnings per share declined 9.4% to SEK 9.59 (10.58)
  • EBITA before restructuring decreased 1.7% to SEK 4,766 M (4,849).
    Adjusted for exchange-rate effects and the medical device tax introduced in the US, EBITA rose 8.3%
  • A dividend per share of SEK 4.15 (4.15) is proposed, corresponding to SEK 989 M (989)

Reporting period October – December

  • Order intake rose 4.2% to SEK 6,931 M (6,648), and grew organically by 5.9%
  • Net sales declined 0.8% to SEK 7,757 M (7,816), corresponding to organic growth of 1.3%
  • Profit before tax increased 18.1% to SEK 1,709 M (1,447)
  • EBITA before restructuring increased 6.1% to SEK 2,062 M (1,943). Adjusted for exchange-rate effects and the medical device tax introduced in the US, EBITA rose 14.0%
  • The acquisition of Pulsion Medical Systems is expected to be completed in the first quarter of 2014

Order intake

The Group’s order intake posted a favorable trend for the quarter and grew organically by 5.9%. Accordingly, for the full-year 2013, order intake increased organically by 4.0%, a figure that compares favorably with other global medical technology companies.